Table 1 Publications reporting the clinical efficacy and tolerability of antiseizure medication for treatment of post-stroke epilepsy
From: Seizures and epilepsy in patients with ischaemic stroke
Author | Study design | Participants (n) | Age (years) | Medication (mg) | Period | Seizure recurrence | Tolerability | Limitations |
|---|---|---|---|---|---|---|---|---|
Alvarez-Sabin et al. [38] | Prospective Observational | 48 ischaemic 23 haemorrhagic | 63.9 | GBP 900–1800 mg | 30 months | 18% | Adverse events 38%; discontinued 3% | SN, NR, NP |
Gilad et al. [28] | Prospective Randomised | 64 ischaemic | LTG 67.2 CBZ 67.7 | LTG 25–200 mg CBZ 100–600 mg | 12 months | LTG 28% CBZ 56% | Discontinued LTG 3%, CBZ 31% | SN, NP, NDB |
Kutlu et al. [116] | Prospective Observational | 34 ischaemic | 69.8 | LEV 1000–2000 mg | 17.7 months | 18% | Discontinued 21%; stopped 3% | SN, NR, NP |
Belcastro et al. [30] | Prospective Observational | 35 ischaemic | 71.9 | LEV 1000–2000 mg | 18 months | 9% | Discontinued 11% | SN, NR, NP |
Consoli et al. [32] | Prospective Randomised | 79 ischaemic 27 haemorrhagic | LEV 74.1 CBZ 54 | LEV 52 CBZ 54 | 13,5Â months | LEV 6% CBZ 15% | Discontinued LEV 33%, CBZ 39% | SN, NP, NDB |
Tanaka and Ihara [117] | Retrospective Observational | 69 ischaemic 43 haemorrhagic | 72.3 | 23 VPA, 22 PHT 15 CBZ | 12 months | VPA 48% PHT 18% CBZ 13% | – | SN, mono- and polytherapy |
Huang et al. [118] | Retrospective Observational | 1729 ischaemic 1893 haemorrhagic | 60.3 | PHT 2507 VPA 712 CBZ 157 Newer ASM 246 | 100 person - months | PHT 1.05% (ER visits) VPA 0.7% CBZ 0.4% Newer ASM 0.38% | – | Seizure in first 3 months excluded |
Sales et al. [39] | Retrospective Observational | 76 PSE 1590 EPI* | PSE 63 EPI 61.4 | ESL/PSE 887 ESL/EPI 983 | 12Â months | 51.4% 68.3% | Adverse events 36% versus 35.8% | Multicentric, differences between cohorts |